The Canadian Broadcasting Corporation’s (CBC) program, The Current, reported: “Drug to treat Female Orgasmic Disorder under speculation.”
The brief program description:
“Trials of a new drug to help treat a condition known as female orgasmic disorder are underway in Canada. But critics say there’s no such thing, and this is really about drug manufacturing and marketing.”
The healthy skeptic on the program (about 12 minutes deep in the audio below) was Dr. Barbara Mintzes, Assistant Professor in the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia. The main focus of her research is on the effects of drug promotion, including direct-to-consumer advertising, on prescribing and medicine use. She also works with UBC’s Therapeutics Initiative to carry out systematic reviews on the beneficial and harmful effects of new drugs. She’s also co-author of the book, “Sex, Lies and Pharmaceuticals: How Drug Companies Plan to Profit from Female Sexual Dysfunction.”
PLAY THE PROGRAM HERE
The program is a classic discussion of concerns about disease-mongering. Kudos to CBC and The Current for educating listeners. It’s a 24-minute program well worth your time.
Opinions on other issues in news, journals, PR, advertising, marketing
“Not everything published in a medical journal is newsworthy, proven, or even important.” https://t.co/J37btponS6
@chrishendel @HealthNewsRevu I believe that "What Would Gary Think?" should be a kneejerk response to any 'junk food causes blindness'-type single case.... 🥴
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like